Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289353 · ClinicalTrials.gov registry record · Phase 1
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT01289353 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 92 participants.
The verdict
NCT01289353, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.
Interventions
- DRUG Carboplatin
- RADIATION 3D-RT or IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2009-03-06 |
| Est. Completion | 2019-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289353
The ClinicalTrials.gov registry entry for NCT01289353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01289353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289353 about?
NCT01289353 is a clinical study titled "Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer". The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.
What is the current status of trial NCT01289353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2009-03-06. Estimated completion is 2019-07-08.
What interventions are being tested in trial NCT01289353?
The interventions under investigation include: Carboplatin (DRUG), 3D-RT or IMRT (RADIATION).
Who is sponsoring clinical trial NCT01289353?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.